Briviact Injection, Suspension
Product Images NDC 50474-970

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Briviact (NDC 50474-970). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Brivaracetam 01)

FDA Label Image

Figure 1 (Brivaracetam 02)

FDA Label Image

Principal Display Panel (10 mg Tablet Bottle Carton)

Each tablet of this medication contains 10 mg of brivaracetam. The usual dosage and additional information are available in the accompanying instructions. The tablets should be stored at a controlled room temperature of 25°C with excursions permitted between 15-30°C. Manufacturer, NDC and other details are also provided in the text.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Carton)

Each tablet of this medication contains 25mg of Erivaracoram. The usual dosage is not available and needs to be obtained from the prescribing information. Store the medication between 15°C to 30°C (25°F to 86°F) and excursions omitted at 25°C (77°F). The medication is named BRIVIACT® and is available in tablet form. The medication is Rxonly, and each container has 60 tablets. The medication guide is recommended to be provided to each patient along with the prescription.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Carton)

BRIVIACT® (brivaracetam) is a medication available in the form of tablets containing 50mg of brivaracetam. The usual dosage should be prescribed by the doctor, and each patient should be dispensed with an accompanying medication guide by the pharmacist. BRIVIACT® should be stored at 25 °C, with limited excursions allowed between 15 °C to 30°C. The manufacturer of this medication is UCB, Inc., located in Syngenta.*

FDA Label Image

Principal Display Panel (75 mg Tablet Bottle Carton)

BRIVIACT® (brivaracetam) tablets contain 75mg of brivaracetam and are categorized as Rxonly drugs. The medication guide should be dispensed to each patient along with the tablets. The usual dosage must be determined by accompanying prescribing information. The tablets should be stored at a controlled room temperature between 15°C and 30°C (59°F to 86°F). Each bottle contains 60 tablets.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Carton)

BRIVIACT® (brivaracetam) is a medication available in tablet form. Each tablet contains 100mg of erivaracatam. It is recommended to store it at 25°C (77°F) with excursions allowed between 15 to 30°C. This medication is Rxonly meaning it requires a prescription to purchase. The recommended dosage is available in the proscribing information. Additional information can be found on the accompanying medication guide.*

FDA Label Image

Principal Display Panel (10 mg/mL Bottle Carton)

Briviact oral solution is a prescription medication containing the active ingredient brivaracetam. The oral solution is available in bottles of 300 mL, with each milliliter containing 10mg of the active ingredient. This medication is stored at temperatures between 15°C to 30°C and must not be frozen. Once opened, unused solution should be discarded after 5 months. To ensure safe use, pharmacists should dispense the accompanying medication guide to each patient. Briviact oral solution is manufactured by UCB, Inc. in Smyrna, GA, and is made in Belgium.*

FDA Label Image

Principal Display Panel (50 mg/5 mL Vial Carton)

BRIVIACT® is an injectable medication with a usual dosage specified in the accompanying prescribing information. It is manufactured for UCB, Inc. and is available in 50 mg/5 mL strength. The medication must be stored at room temperature and should not be frozen. The pack contains 10 vials of the drug intended for intravenous use only. The NDC number of the medication is 50474-970-75. No other useful information can be obtained from the text obtained by .*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.